Results 211 to 220 of about 1,582,904 (250)

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1489-1498, September 2026.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Repurposing of lansoprazole and nitazoxanide as NR2F2 inhibitors in the gastric cancer cell line GCIY: computational insights and siRNA-mediated <i>in vitro</i> tests. [PDF]

Front Chem
Culletta G, Roomi MS, Caricasulo MA, Zanetti A, Terao M, Paroni G, Garattini E, Tutone M.   +7 more
europepmc   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1533-1537, September 2026.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike, Yoko Irie, Yuji Doi, Ryosuke Kemmotsu, Moe Kusushita, Yasuna Sakai, Tomonori Okita, Hiroyuki Sho, Ryoko Inui, Yukiko Tabuchi, Tetsuyuki Yasuda   +10 more
wiley   +1 more source

Combined In Vitro and Computational Investigations on Synthesized Sulfonamide-Based Antidiabetic Agents. [PDF]

Pharmaceuticals (Basel)
Iacob AD, Cioancă O, Aprodu I, Tatia R, Iacob AT, Mircea C, Tutunaru D, Pavel AB, Lungu II, Dragostin OM.   +9 more
europepmc   +1 more source

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1538-1547, September 2026.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

Sarcopenia and chronic pain: Identification of shared genetic determinants and therapeutic implication. [PDF]

Medicine (Baltimore)
Li J, Huang J, Han J.
europepmc   +1 more source

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1565-1574, September 2026.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori, Kasei Ko, Satoko Notomi, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Saeko Osawa, Tsunehiko Yamamoto, Akio Kuroda, Munehide Matsuhisa   +12 more
wiley   +1 more source

Design and evolution of the tetracycline repressor into sulfonylurea herbicide-responsive gene switches for field crops. [PDF]

Nat Commun
McBride KE, Kakani NK, Bozhanova NG, Fang J, Lowe K, Leija C, McGonigle B, Schreiter ER, Hermanson F, Chan M, Arling M, Wang N, Cho HJ, Richey C, Hoerster G, Marvin JS, Lenderts B, McReynolds MR, Hastings C, Madrigal A, Falco SC, Lassner MW, Anand A, Gordon-Kamm W, Looger LL.   +24 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8724-8728, September 2026.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Health System Integration and Equity in Type 2 Diabetes Prevention: A Comparative Policy Analysis of Seven National Guidelines

Journal of Evaluation in Clinical Practice, Volume 32, Issue 6, September 2026.
ABSTRACT Rationale Type 2 diabetes mellitus affects more than 500 million adults worldwide, yet up to 80% of related complications are preventable through evidence‐based care. Clinical practice guidelines function as key prevention policy instruments; however, their implementation and integration into health systems vary substantially, with important ...
Richard Marfo, Dennis Miezah, Rockson Ansong, Musah Abubakari, Evans F. Kyei   +4 more
wiley   +1 more source